Pinpointing islet autoantibodies associated with type 1 diabetes (T1D) leads the way to project and deter this disease in the general population. A novel ECL assay is a nonradioactive fluid phase assay for islet autoantibodies with higher sensitivity and specificity than the current 'gold' standard radio-binding assay (RBA). ECL assays can more precisely define the onset of presymptomatic T1D by distinguishing the high-risk, high-affinity autoantibodies from the low-risk, low-affinity autoantibodies generated in RBAs, and conventional enzyme-linked immunosorbent assays (ELISA). The antigen protein used in this ECL assay is labeled with Sulfo-tag and Biotin, respectively. Each ECL autoantibody assay that uses a particular antigen protein needs an optimization step before it can be used for laboratory application. This step is especially vital in determining the requirements for serum acid treatments, concentrations, and ratios of the two different antigens labeled with Sulfo-tag and Biotin. To perform the assay, serum samples are mixed with Sulfo-tag-conjugated and biotinylated capture antigen protein in phosphate buffered solution (PBS), containing 5% Bovine Serum Albumin (BSA). Afterwards, the samples are incubated overnight at 4 °C. The same day, a streptavidin-coated plate is prepared with blocker buffer and incubated overnight at 4 °C. On the second day, wash the streptavidin plate and transfer the serum-antigen mixture onto the plate. Place the plate on the plate shaker, set it at low speed, and incubate at room temperature for 1 h. Subsequently, the plate is washed again, and reader buffer is added. The plate is then counted on the plate reader machine. The results are conveyed through an index, which is generated from internal standard positive and negative control serum samples.
Introduction
A recent staging classification system has been created to assist with the diagnosis of initial stages of T1D in patients. Exact detection of human islet autoantibodies plays an important role in identifying and staging presymptomatic type 1 diabetes, as the presence of islet autoantibodies indicates the presence of β-cell autoimmunity. The rate at which diabetes affects patients from the initial occurrence of β-cell autoimmunity to the symptomatic disease, associated with the number and type of islet autoantibodies, is variable 2, 3 .
The age of autoantibody seroconversion, titer, and affinity of islet autoantibodies can affect the rate of the progression to symptomatic type 1 diabetes 4, 5, 6, 7, 8, 9, 10 . Recently, developed ECL assays have been extensively validated, have demonstrated increased sensitivity, and are more disease-specific 10, 11, 12, 13 . These assays enhance the prediction and staging of diabetes risk through earlier detection of islet autoantibodies. They more precisely mark the initiation of islet autoimmunity and ignore the low-affinity and low risk signals not relevant to diabetes.
In an ECL assay, the autoantibodies in the serum, if present, bridge the Sulfo-tag-conjugated antigen to the biotinylated capture antigen in the fluid phase. After bridging, the Biotin linker is caught in the solid phase and detected through ECL by the Sulfo-tag on the streptavidin coated plate (Figure 1) .
In this review, single antibody ECL assays with human islet autoantibodies are primarily utilized. Briefly, multiplexed antibody assays based on single ECL assays will be discussed. The multiplex assay can be used to identify multiple, up to 10, autoantibodies within one single well, using 15 µL of serum. This simple high throughput assay can be used to screen, simultaneously, multiple autoantibodies for multiple relevant autoimmune diseases in the general population. 
Prepare the Antigen Buffer Using the Correct Concentration of Biotin/Sulfo-tag Labeled Antigen
1. Select the rational concentration of each antigen based on the checker board assay. 2. Prepare 3 mL of antigen solution per plate, using the rational concentration of Biotin/Sulfo-tag labeled antigen for the antigen buffer.
Incubate Serum Samples with Labeled Antigen
Note: There are two protocols in this section, one without serum acid treatment and one with serum acid treatment. All islet autoantibody assays except IAA assay use regular protocol without serum acid treatment from steps 5.1 to 5.5, whereas IAA assay skips these steps and uses protocol with serum acid treatment from steps 5.6 to 5.9.
Representative Results
Figure 2 displays the checker board. It is shown that 250 ng/mL of Biotin and 250 ng/mL of Sulfo-tag labeled antigen are the most rational concentrations used in the assay considering the signals from the high positive control sample, the negative control sample as the assay's background, and the ratio of positive to negative signals. With the optimized concentrations of these two labeled antigens, the assay was performed with the serum samples from 100 newly diagnosed patients with T1D and 100 healthy controls. The index value of 0.023 was defined as the assay cut-off for positivity. This represents 85% sensitivity in patients and 99% specificity in healthy controls using the receiver operating characteristic (ROC) curve shown in Figure 3A . The assay for the unknown samples was conducted with internal standard high positives, low positives, and negative control samples. The results of the CPS counts are shown in Table 2A . These values will be defined as the positive results that are greater than the 99 th percentile of the healthy control population. When an irrational antigen concentration
In ECL assays, for some particular autoantibodies like IAA, the binding of autoantibodies to the antigen seems to be inhibited by some component present in normal human serum. To remove or release this inhibition, acid treatment of serum samples was necessary to do before the serum was incubated with antigen. As shown in [ Figure 5 ], ECL-IAA assay, the binding activities of both the mouse insulin monoclonal antibody and patients' serum autoantibodies with the antigen was greatly enhanced. The acidification of serum samples, used in antibody assays, is usually applied to disassociate pre-existing bound complexes. The mechanism behind how IAA signals are inhibited in human serum samples and released by acidification of serum is not known, but this method has been used in other ECL based assays 14, 15 .
In a few cases, when labeling molecules, either Biotin or Sulfo-tag, the labeling positionsinside of the antigen protein molecules are at, or very close to key epitopes of antibody binding, which may interfere with the binding activity to antibodies. This will reduce assay sensitivity and can completely tear down the assay. For routine labeling procedure, maximization or saturation is desired for each antigen protein molecule to generate maximum activity or signal per labeled molecule by maximizing labeling capacity of every possible labeling position. Unsaturated labeling should be performed by reducing the molar ratio of labeling molecules (Biotin and Sulfo-tag) to the antigen protein if labeling on the antigen becomes a possible reason for interruption of antibody binding activity. Major epitopes can be better reserved and interruption of antibody binding activity can be released using the unsaturated labeling strategy in most cases.
Each assay should include an internal standard high positive and negative control for index calculations of unknown samples. A low positive control near the assay's upper limit of normal controls is important to include for the monitoring of assay sensitivity. The laboratory should keep enough aliquots of standard positive and negative controls for long-term use and all aliquots should be stored at -20 °C. For assay quality assurance, assays must be run in duplicates for each sample and every positive result should be confirmed by repeating the sample in a separate assay. A third assay is necessary when the second confirmatory assay does not agree with the first assay and the results of two assays, which agree (e.g., +,+ or -,-), will be the final determination of a positive or negative result.
With the platform set for single ECL assays, a multiplexed assay can be expanded upon from these. It can simultaneously determine up to 10 different autoantibodies in one single well with a tiny amount of serum. Currently, four islet autoantibodies including IAA, GADA, IA-2A, and ZnT8A are equal in importance for the risk prediction of progression to T1D in both relatives of patients with T1D and the general population. The methods utilized for screening these 4 autoantibodies using current single autoantibody measurements are laborious and inefficient, especially for large scale population screening. Importantly, up to 40% of patients with T1D have an additional autoimmune condition 16, 17, 18 . Unfortunately, there is no easy and inexpensive tool to screen for these conditions. The multiplex ECL assay is not only capable of combining 4 current major islet autoantibody assays into one, but also is able to further combine more autoantibody assays from other relevant autoimmune diseases. This makes it possible to efficiently conduct high throughput screening for multiple autoimmune diseases simultaneously in large scale populations. In the multiplex ECL assay, as shown in [ Figure 6 ], each antibody-antigen complex formed in the fluid-phase will be restrained to a specific linker source spot in the same well. The signal receiver on the plate reader machine is able to recognize the signals from 10 different sources of spots. However, the spots with an extremely high signal can generate a high assay background and cause interference to neighboring spots through cross-talk. For this reason, the upper limit signals for each autoantibody assay should be limited to fewer than 20,000 counts. In our experience, the autoantibodies with lower backgrounds should be placed relatively far away from those spots having higher counts when the spot map is designed. For long-term studies using multiplex ECL assays, it is recommended that the same linker be used for the same autoantibody assay to keep the assay consistent.
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